Method for treating radiation esophagitis by using improved tissue-promoting jade red cream oil

Abstract

The invention relates to the technical field of treatment of improved granulation-promoting jade red cream oil, and discloses a method for treating radiation esophagitis by using the improved granulation-promoting jade red cream oil, which preliminarily clarifies the fluctuation condition of TNF-a and IL-8 in the body of a patient with radiation esophagitis, and detects the content of TNF-a and IL-8 in the body fluid of the patient by adopting an enzyme-linked immunosorbent assay. The pathogenesis of radioactive esophagitis is analyzed; the mechanism of radioactive esophageal trauma inflammation, IL-8 and the interaction of IL-8 in the intervention of the improved granulation-promoting jade red cream oil agent is explored, and the influence of the improved granulation-promoting jade red cream oil agent on the radioactive esophageal inflammation reaction is researched through in-vitro experiments and animal models; evaluating the curative effect of the improved tissue-engendering jade red cream oil on radiation esophagitis, analyzing the influence of the improved tissue-engendering jade red cream oil on esophageal mucosa epithelium apoptosis caused by radiation injury, and observing the treatment effect of the improved tissue-engendering jade red cream oil through random contrast clinical tests; a good treatment effect can be achieved, the treatment expenditure is reduced for patients, and the medical insurance burden is relieved.

Description

Technical Field

[0001] The invention relates to the technical field of improved Shengji Yuhong ointment and oil treatment, and specifically to a method for treating radiation esophagitis by utilizing the improved Shengji Yuhong ointment and oil. Background Art

[0002] Radiation esophagitis is one of the main complications of mediastinal radiotherapy for the treatment of lung cancer, esophageal cancer, mediastinal malignancies or head and neck malignancies. In the second to third week of radiotherapy, when the radiation dose reaches 20-40Gy, the esophageal mucosa will undergo pathological damage such as dilation, congestion, edema and even erosion. This causes patients to have difficulty swallowing, ache swallowing, and a burning sensation in the sternum, which brings great pain to patients during the treatment of tumors worldwide.

[0003] There are about 130,000 new cancer patients in Anhui Province every year. Currently, about 70% of cancer patients need to receive radiotherapy. When radiotherapy is performed on the chest and mediastinum, the occurrence of radiation esophagitis is inevitable. For radiation esophagitis caused by radiotherapy, the current treatment methods for radiation esophagitis are limited and the effect is not good. Western medicine treatment mainly includes reducing mucosal edema, pain relief, anti-inflammatory and symptomatic treatment. The clinical efficacy is general, the side effects are large, and the economic burden on patients is increased. Therefore, it is necessary to design a corresponding technical solution to solve it. Summary of the invention

[0004] 1. Technical issues to be resolved

[0005] In view of the deficiencies in the prior art, the present invention provides a method for treating radiation esophagitis using an improved Shengji Yuhong ointment, which solves the technical problems that the treatment methods for radiation esophagitis are limited and the effects are not good, and Western medicine treatment mainly includes reducing mucosal edema, relieving pain, reducing inflammation and symptomatic treatment, with general clinical efficacy, large side effects and increased economic burden on patients.

[0006] (II) Technical solution

[0007] To achieve the above objectives, the present invention is implemented by the following technical scheme: a method for treating radiation esophagitis using improved Shengji Yuhong ointment, the steps are as follows:

[0008] S1, preliminarily clarify the fluctuation of TNF-a and IL-8 in patients with radiation esophagitis, use enzyme-linked immunosorbent assay to detect the content of TNF-a and IL-8 in patient body fluids, and analyze the pathogenesis of radiation esophagitis;

[0009] S2, explore the mechanism of radiation esophageal trauma inflammation, IL-8 and their interaction in the intervention of modified Shengji Yuhong ointment, and study the effect of modified Shengji Yuhong ointment on radiation esophageal inflammatory response through in vitro experiments and animal models;

[0010] S3, to evaluate the efficacy of the modified Shengji Yuhong ointment in the treatment of radiation esophagitis, to analyze the effect of the modified Shengji Yuhong ointment on apoptosis of esophageal mucosal epithelium damaged by radiation, and to observe the therapeutic effect of the modified Shengji Yuhong ointment through a randomized controlled clinical trial;

[0011] S4, study the effective ingredients, therapeutic mechanism and basic pharmacology of the action link in the improved formula of Shengji Yuhong ointment;

[0012] S5, to explore the mechanism of connection between cytokines and the treatment of modified Shengji Yuhong ointment, and to provide a basis for early intervention of radiation esophagitis;

[0013] S6, according to the research results of steps S1-S5, determine the optimal composition and dosage of the improved Shengji Yuhong ointment;

[0014] S7, preparing the improved Shengji Yuhong ointment according to the optimal composition and dosage determined in step S6;

[0015] S8, apply the prepared improved Shengji Yuhong ointment to the treatment of patients with radiation esophagitis and observe its efficacy;

[0016] S9, compare the advantages and disadvantages of the modified Shengji Yuhong ointment with other treatments in the treatment of radiation esophagitis, and evaluate the clinical application value of the modified Shengji Yuhong ointment;

[0017] S10, summarize the overall efficacy and application prospects of the improved Shengji Yuhong ointment in the treatment of radiation esophagitis, and provide a reference for subsequent research and clinical application.

[0018] Preferably, in step S1, the detection of TNF-a and IL-8 in the patient's body fluid is performed by enzyme-linked immunosorbent assay (ELISA), and the main steps include:

[0019] Prepare a series of standard dilutions and draw a standard curve;

[0020] Select a dilution factor of 1-5 times according to the expected concentration of the sample and prepare the sample dilution solution;

[0021] Add standard diluent, sample diluent and reagents required for detection to the ELISA plate, and perform washing, incubation and color development according to the instructions of the kit;

[0022] The absorbance value of each well was measured using an ELISA reader, and the concentrations of TNF-a and IL-8 in the samples were calculated according to the standard curve;

[0023] Based on the test results, combined with the patient's medical history and symptoms, the possible pathogenesis of radiation esophagitis was analyzed.

[0024] Preferably, in step S2, the in vitro experiment:

[0025] Normal human esophageal mucosal epithelial cells were cultured and irradiated with γ-rays to establish a radiation injury model.

[0026] Different concentrations of modified Shengji Yuhong ointment were added to the model group to detect cell proliferation, apoptosis or ROS indicators;

[0027] To detect the levels of inflammatory factors IL-8 and TNF-α, and to observe the effects of the modified Shengji Yuhong ointment on cell damage and inflammatory factors;

[0028] Animal Model:

[0029] A mouse radiation esophagitis model was established to damage the esophageal tissue by local irradiation;

[0030] The patients were divided into groups and given different doses of modified Shengji Yuhong ointment, and a blank control group was set up.

[0031] Observe the pathological changes of esophageal tissues and detect the inflammatory factor IL-8 and inflammatory cell infiltration;

[0032] To analyze the protective effect of the improved Shengji Yuhong ointment on radiation esophagitis and its effect on IL-8 and inflammatory cells.

[0033] Preferably, in step S3, the effect of the improved Shengji Yuhong ointment on apoptosis of esophageal mucosal epithelium damaged by radiation is analyzed:

[0034] Esophageal mucosal tissue specimens were collected from patients with radiation esophagitis before and after treatment for apoptosis detection;

[0035] The changes of apoptosis index of mucosal epithelial cells before and after treatment were analyzed;

[0036] To observe whether the improved Shengji Yuhong ointment can reduce the apoptosis of mucosal epithelium caused by radiation;

[0037] Clinical efficacy evaluation:

[0038] Design a randomized controlled clinical trial and divide the cases into a treatment group and a control group;

[0039] The treatment group was given the modified Shengji Yuhong ointment, and the control group was given ordinary treatment.

[0040] The improvement of clinical symptoms and signs, inflammatory cell infiltration of esophageal mucosa, gastroesophageal reflux and other indicators were observed in the two groups of patients.

[0041] To evaluate the clinical therapeutic effect of the improved Shengji Yuhong ointment.

[0042] Preferably, step S4 includes identification of active ingredients, research on drug efficacy mechanisms and basic pharmacology research;

[0043] Identification of active ingredients:

[0044] Using chromatographic separation technology such as HPLC to separate and extract the chemical components in the improved Shengji Yuhong ointment;

[0045] Use mass spectrometry to identify the structure of each chemical component;

[0046] Screening for pharmacologically active ingredients through activity tracking and separation methods;

[0047] Study on drug efficacy mechanism:

[0048] Observe the changes of key effector substances in radiation esophagitis cell models and animal models;

[0049] Use molecular biology techniques to detect the expression of key genes and signaling pathways;

[0050] To explore the target and mechanism of action of the improved Shengji Yuhong ointment;

[0051] Basic pharmacology research:

[0052] The pharmacological effects of the drug were observed in normal and radiation esophagitis models;

[0053] To observe the effect of the improved Shengji Yuhong ointment on inflammation, immunity, etc.

[0054] To explore the pharmacological characteristics and indications of the improved Shengji Yuhong ointment.

[0055] Preferably, in step S5, a radioactive esophagitis cell model is established, and after γ-ray irradiation, different concentrations of modified Shengji Yuhong ointment are added for intervention; changes in the levels of inflammatory factors IL-1β, IL-6 or TNF-α in the model group and the intervention group are detected; in the radioactive esophagitis animal model, the modified Shengji Yuhong ointment is given for intervention, the pathological changes of esophageal tissue are observed, and the expression levels of the above-mentioned inflammatory factors are detected; the activity changes of NF-κB and MAPK signaling pathway molecules are detected by PCR and Western blot methods; it is explored whether the modified Shengji Yuhong ointment can downregulate the expression of inflammatory factors and inhibit the activation of the key inflammatory pathway of NF-κB; the relationship between inflammatory factors and the modified Shengji Yuhong ointment is studied by methods such as inflammatory factor antibody neutralization; and the changes in the levels of inflammatory factors before and after treatment are detected in patients.

[0056] Preferably, in step S6, the improved Shengji Yuhong ointment comprises 10 mL of safflower oil, 5 mL of cnidium monnieri oil, 0.5 g of Yuhong ointment, 0.5 g of raw milk, and an appropriate amount of anti-inflammatory and dehumidifying prescription.

[0057] (III) Beneficial effects

[0058] The method of using the improved Shengji Yuhong ointment to treat radiation esophagitis can achieve good therapeutic effects, reduce treatment expenses for patients, reduce the burden of medical insurance, effectively reduce the use rate of antibiotics in hospitals, and increase the clinical use and benefits of Chinese medicine prescriptions by 50%, forming an effective promotion for municipal and county hospitals. The improved oil-immersion prescription has the effects of detoxification, swelling, tissue regeneration and pain relief. Through multiple clinical case studies, it was observed that the improved Shengji Yuhong ointment had a definite clinical efficacy, providing an experimental basis for further promotion of clinical drug use. DETAILED DESCRIPTION

[0059] The technical solutions in the embodiments of the present invention are described clearly and completely. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0060] The embodiment of the present invention provides a technical solution: a method for treating radiation esophagitis using the improved Shengji Yuhong ointment, the steps of which are as follows:

[0061] S1, preliminarily clarify the fluctuation of TNF-a and IL-8 in patients with radiation esophagitis, use enzyme-linked immunosorbent assay to detect the content of TNF-a and IL-8 in patient body fluids, and analyze the pathogenesis of radiation esophagitis;

[0062] S2, explore the mechanism of radiation esophageal trauma inflammation, IL-8 and their interaction in the intervention of modified Shengji Yuhong ointment, and study the effect of modified Shengji Yuhong ointment on radiation esophageal inflammatory response through in vitro experiments and animal models;

[0063] S3, to evaluate the efficacy of the modified Shengji Yuhong ointment in the treatment of radiation esophagitis, to analyze the effect of the modified Shengji Yuhong ointment on apoptosis of esophageal mucosal epithelium damaged by radiation, and to observe the therapeutic effect of the modified Shengji Yuhong ointment through a randomized controlled clinical trial;

[0064] S4, study the effective ingredients, therapeutic mechanism and basic pharmacology of the action link in the improved formula of Shengji Yuhong ointment;

[0065] S5, to explore the mechanism of connection between cytokines and the treatment of modified Shengji Yuhong ointment, and to provide a basis for early intervention of radiation esophagitis;

[0066] S6, according to the research results of steps S1-S5, determine the optimal composition and dosage of the improved Shengji Yuhong ointment;

[0067] S7, preparing the improved Shengji Yuhong ointment according to the optimal composition and dosage determined in step S6;

[0068] S8, apply the prepared improved Shengji Yuhong ointment to the treatment of patients with radiation esophagitis and observe its efficacy;

[0069] S9, compare the advantages and disadvantages of the modified Shengji Yuhong ointment with other treatments in the treatment of radiation esophagitis, and evaluate the clinical application value of the modified Shengji Yuhong ointment;

[0070] S10, summarize the overall efficacy and application prospects of the improved Shengji Yuhong ointment in the treatment of radiation esophagitis, and provide a reference for subsequent research and clinical application.

[0071] Further improved, in step S1, the detection of TNF-a and IL-8 in the patient's body fluid is carried out by enzyme-linked immunosorbent assay (ELISA), and the main steps include:

[0072] Prepare a series of standard dilutions and draw a standard curve;

[0073] Select a dilution factor of 1-5 times according to the expected concentration of the sample and prepare the sample dilution solution;

[0074] Add standard diluent, sample diluent and reagents required for detection to the ELISA plate, and perform washing, incubation and color development according to the instructions of the kit;

[0075] The absorbance value of each well was measured using an ELISA reader, and the concentrations of TNF-a and IL-8 in the samples were calculated according to the standard curve;

[0076] Based on the test results, combined with the patient's medical history and symptoms, the possible pathogenesis of radiation esophagitis was analyzed.

[0077] Further improved, in step S2, in vitro experiment:

[0078] Normal human esophageal mucosal epithelial cells were cultured and irradiated with γ-rays to establish a radiation injury model.

[0079] Different concentrations of modified Shengji Yuhong ointment were added to the model group to detect cell proliferation, apoptosis or ROS indicators;

[0080] To detect the levels of inflammatory factors IL-8 and TNF-α, and to observe the effects of the modified Shengji Yuhong ointment on cell damage and inflammatory factors;

[0081] Animal Model:

[0082] A mouse radiation esophagitis model was established to damage the esophageal tissue by local irradiation;

[0083] The patients were divided into groups and given different doses of modified Shengji Yuhong ointment, and a blank control group was set up.

[0084] Observe the pathological changes of esophageal tissues and detect the inflammatory factor IL-8 and inflammatory cell infiltration;

[0085] To analyze the protective effect of the improved Shengji Yuhong ointment on radiation esophagitis and its effect on IL-8 and inflammatory cells.

[0086] Further improved, in step S3, the effect of the improved Shengji Yuhong ointment on apoptosis of esophageal mucosal epithelium damaged by radiation is analyzed:

[0087] Esophageal mucosal tissue specimens were collected from patients with radiation esophagitis before and after treatment for apoptosis detection;

[0088] The changes of apoptosis index of mucosal epithelial cells before and after treatment were analyzed;

[0089] To observe whether the improved Shengji Yuhong ointment can reduce the apoptosis of mucosal epithelium caused by radiation;

[0090] Clinical efficacy evaluation:

[0091] Design a randomized controlled clinical trial and divide the cases into a treatment group and a control group;

[0092] The treatment group was given the modified Shengji Yuhong ointment, and the control group was given ordinary treatment.

[0093] The improvement of clinical symptoms and signs, inflammatory cell infiltration of esophageal mucosa, gastroesophageal reflux and other indicators were observed in the two groups of patients.

[0094] To evaluate the clinical therapeutic effect of the improved Shengji Yuhong ointment.

[0095] In a further improvement, step S4 includes identification of active ingredients, research on drug efficacy mechanisms and basic pharmacological research;

[0096] Identification of active ingredients:

[0097] Using chromatographic separation technology such as HPLC to separate and extract the chemical components in the improved Shengji Yuhong ointment;

[0098] Use mass spectrometry to identify the structure of each chemical component;

[0099] Screening for pharmacologically active ingredients through activity tracking and separation methods;

[0100] Study on drug efficacy mechanism:

[0101] Observe the changes of key effector substances in radiation esophagitis cell models and animal models;

[0102] Use molecular biology techniques to detect the expression of key genes and signaling pathways;

[0103] To explore the target and mechanism of action of the improved Shengji Yuhong ointment;

[0104] Basic pharmacology research:

[0105] The pharmacological effects of the drug were observed in normal and radiation esophagitis models;

[0106] To observe the effect of the improved Shengji Yuhong ointment on inflammation, immunity, etc.

[0107] To explore the pharmacological characteristics and indications of the improved Shengji Yuhong ointment.

[0108] Further improved, in step S5, a radioactive esophagitis cell model is established, and after γ-ray irradiation, different concentrations of modified Shengji Yuhong ointment are added for intervention; the changes in the levels of inflammatory factors IL-1β, IL-6 or TNF-α in the model group and the intervention group are detected; in the radioactive esophagitis animal model, the modified Shengji Yuhong ointment is given for intervention, the pathological changes of esophageal tissue are observed, and the expression levels of the above-mentioned inflammatory factors are detected; the activity changes of NF-κB and MAPK signaling pathway molecules are detected by PCR and Western blot methods; it is explored whether the modified Shengji Yuhong ointment can downregulate the expression of inflammatory factors and inhibit the activation of the key inflammatory pathway of NF-κB; the relationship between inflammatory factors and the modified Shengji Yuhong ointment is studied by methods such as inflammatory factor antibody neutralization; and the changes in the levels of inflammatory factors before and after treatment are detected in patients.

[0109] Further improved, in step S6, the improved Shengji Yuhong ointment comprises 10 mL of safflower oil, 5 mL of cnidium monnieri oil, 0.5 g of Yuhong ointment, 0.5 g of raw milk, and an appropriate amount of anti-inflammatory and dehumidifying prescription.

[0110] TNF-a is a pro-inflammatory factor, and elevated levels indicate an active inflammatory response.

[0111] IL-8 is an inflammatory chemokine, and elevated levels indicate inflammatory cell infiltration.

[0112] Radiation esophagitis can cause esophageal mucosal damage, promote the release of cytokines such as TNF-a and IL-8, and trigger inflammatory responses and tissue damage.

[0113] By detecting changes in the levels of these cytokines in the patient's body fluids, the severity of the inflammatory response can be determined, providing a basis for evaluating the condition and providing treatment.

[0114] Embodiment 1:

[0115] Thirty patients with radiation esophagitis were selected as the research subjects. The levels of TNF-a and IL-8 in the patients' body fluids were detected by enzyme-linked immunosorbent assay to analyze the pathogenesis of radiation esophagitis.

[0116] The results showed that the levels of TNF-a and IL-8 were significantly increased in patients with radiation esophagitis.

[0117] Embodiment 2:

[0118] The effect of modified Shengji Yuhong ointment on radiation esophageal inflammatory response was studied through in vitro experiments and animal models.

[0119] The results showed that the modified Shengji Yuhong ointment could significantly reduce the degree of radiation-induced esophageal inflammatory response and alleviate IL-8-induced inflammation.

[0120] Embodiment 3:

[0121] Sixty patients with radiation esophagitis were selected and randomly divided into an experimental group and a control group to observe the therapeutic effect of the improved Shengji Yuhong ointment.

[0122] The results of the study showed that the improved Shengji Yuhong ointment had a significant inhibitory effect on esophageal mucosal epithelial apoptosis, and its clinical efficacy was significantly better than that of the control group.

[0123] Embodiment 4:

[0124] An in-depth study of the formula of the improved Shengji Yuhong ointment revealed that its main active ingredients are Chinese herbal medicine extracts, which work together to exert anti-inflammatory, analgesic, and repair-promoting effects, thereby achieving the purpose of treating radiation esophagitis.

[0125] Embodiment 5:

[0126] The present invention conducts an in-depth discussion on the connection mechanism between the improved Shengji Yuhong ointment and cytokines, and finds that the improved Shengji Yuhong ointment can improve the inflammatory environment in patients with radiation esophagitis by regulating cytokine levels, thereby achieving the purpose of treating radiation esophagitis.

[0127] The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It is obvious to those skilled in the art that the present invention is not limited to the details of the above exemplary embodiments, and the present invention can be implemented in other specific forms without departing from the spirit or basic features of the present invention. Therefore, no matter from which point of view, the embodiments should be regarded as exemplary and non-restrictive. The scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes that fall within the meaning and scope of the equivalent elements of the claims are included in the present invention.

[0128] In addition, it should be understood that although the present specification is described according to implementation modes, not every implementation mode contains only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation modes that can be understood by those skilled in the art.

Claims

1. A method for treating radiation esophagitis using improved Shengji Yuhong ointment, characterized in that: The steps are as follows: S1, preliminarily clarify the fluctuation of TNF-a and IL-8 in patients with radiation esophagitis, use enzyme-linked immunosorbent assay to detect the content of TNF-a and IL-8 in patient body fluids, and analyze the pathogenesis of radiation esophagitis; S2, explore the mechanism of radiation esophageal trauma inflammation, IL-8 and their interaction in the intervention of modified Shengji Yuhong ointment, and study the effect of modified Shengji Yuhong ointment on radiation esophageal inflammatory response through in vitro experiments and animal models; S3, to evaluate the efficacy of the modified Shengji Yuhong ointment in the treatment of radiation esophagitis, to analyze the effect of the modified Shengji Yuhong ointment on apoptosis of esophageal mucosal epithelium damaged by radiation, and to observe the therapeutic effect of the modified Shengji Yuhong ointment through a randomized controlled clinical trial; S4, study the effective ingredients, therapeutic mechanism and basic pharmacology of the action link in the improved formula of Shengji Yuhong ointment; S5, to explore the mechanism of connection between cytokines and the treatment of modified Shengji Yuhong ointment, and to provide a basis for early intervention of radiation esophagitis; S6, according to the research results of steps S1-S5, determine the optimal composition and dosage of the improved Shengji Yuhong ointment; S7, preparing the improved Shengji Yuhong ointment according to the optimal composition and dosage determined in step S6; S8, apply the prepared improved Shengji Yuhong ointment to the treatment of patients with radiation esophagitis and observe its efficacy; S9, compare the advantages and disadvantages of the modified Shengji Yuhong ointment with other treatments in the treatment of radiation esophagitis, and evaluate the clinical application value of the modified Shengji Yuhong ointment; S10, summarize the overall efficacy and application prospects of the improved Shengji Yuhong ointment in the treatment of radiation esophagitis, and provide a reference for subsequent research and clinical application.

2. A method for treating radiation esophagitis using improved Shengji Yuhong ointment according to claim 1, characterized in that: In step S1, TNF-a and IL-8 in the patient's body fluid are detected by enzyme-linked immunosorbent assay (ELISA), and the main steps include: Prepare a series of standard dilutions and draw a standard curve; Select a dilution factor of 1-5 times according to the expected concentration of the sample and prepare the sample dilution solution; Add standard diluent, sample diluent and reagents required for detection to the ELISA plate, and perform washing, incubation and color development according to the instructions of the kit; The absorbance value of each well was measured using an ELISA reader, and the concentrations of TNF-a and IL-8 in the samples were calculated according to the standard curve; Based on the test results, combined with the patient's medical history and symptoms, the possible pathogenesis of radiation esophagitis was analyzed.

3. A method for treating radiation esophagitis using improved Shengji Yuhong ointment according to claim 1, characterized in that: In step S2, in vitro experiment: Normal human esophageal mucosal epithelial cells were cultured and irradiated with γ-rays to establish a radiation injury model. Different concentrations of modified Shengji Yuhong ointment were added to the model group to detect cell proliferation, apoptosis or ROS indicators; To detect the levels of inflammatory factors IL-8 and TNF-α, and to observe the effects of the modified Shengji Yuhong ointment on cell damage and inflammatory factors; Animal Model: A mouse radiation esophagitis model was established to damage the esophageal tissue by local irradiation; The patients were divided into groups and given different doses of modified Shengji Yuhong ointment, and a blank control group was set up. Observe the pathological changes of esophageal tissues and detect the inflammatory factor IL-8 and inflammatory cell infiltration; To analyze the protective effect of the improved Shengji Yuhong ointment on radiation esophagitis and its effect on IL-8 and inflammatory cells.

4. A method for treating radiation esophagitis using improved Shengji Yuhong ointment according to claim 1, characterized in that: In step S3, the effect of the improved Shengji Yuhong ointment on apoptosis of esophageal mucosal epithelium damaged by radiation was analyzed: Esophageal mucosal tissue specimens were collected from patients with radiation esophagitis before and after treatment for apoptosis detection; The changes of apoptosis index of mucosal epithelial cells before and after treatment were analyzed; To observe whether the improved Shengji Yuhong ointment can reduce the apoptosis of mucosal epithelium caused by radiation; Clinical efficacy evaluation: Design a randomized controlled clinical trial and divide the cases into a treatment group and a control group; The treatment group was given the modified Shengji Yuhong ointment, and the control group was given ordinary treatment. The improvement of clinical symptoms and signs, inflammatory cell infiltration of esophageal mucosa, gastroesophageal reflux and other indicators were observed in the two groups of patients. To evaluate the clinical therapeutic effect of the improved Shengji Yuhong ointment.

5. A method for treating radiation esophagitis using improved Shengji Yuhong ointment according to claim 1, characterized in that: Step S4 includes identification of active ingredients, study of drug efficacy mechanisms and basic pharmacology research; Identification of active ingredients: Using chromatographic separation technology such as HPLC to separate and extract the chemical components in the improved Shengji Yuhong ointment; Use mass spectrometry to identify the structure of each chemical component; Screening for pharmacologically active ingredients through activity tracking and separation methods; Study on drug efficacy mechanism: Observe the changes of key effector substances in radiation esophagitis cell models and animal models; Use molecular biology techniques to detect the expression of key genes and signaling pathways; To explore the target and mechanism of action of the improved Shengji Yuhong ointment; Basic pharmacology research: The pharmacological effects of the drug were observed in normal and radiation esophagitis models; To observe the effect of the improved Shengji Yuhong ointment on inflammation, immunity, etc. To explore the pharmacological characteristics and indications of the improved Shengji Yuhong ointment.

6. A method for treating radiation esophagitis using improved Shengji Yuhong ointment according to claim 1, characterized in that: In step S5, a radioactive esophagitis cell model is established, and after γ-ray irradiation, different concentrations of the modified Shengji Yuhong ointment are added for intervention; the changes in the levels of inflammatory factors IL-1β, IL-6 or TNF-α in the model group and the intervention group are detected; in the radioactive esophagitis animal model, the modified Shengji Yuhong ointment is given for intervention, the pathological changes of esophageal tissues are observed, and the expression levels of the above inflammatory factors are detected; the activity changes of NF-κB and MAPK signaling pathway molecules are detected by PCR and Western blot methods; and it is explored whether the modified Shengji Yuhong ointment can downregulate the expression of inflammatory factors and inhibit the activation of the key inflammatory pathway of NF-κB; The relationship between inflammatory factors and the improved Shengji Yuhong ointment was studied through methods such as inflammatory factor antibody neutralization; the changes in inflammatory factor levels before and after treatment were detected in patients.

7. A method for treating radiation esophagitis using improved Shengji Yuhong ointment according to claim 1, characterized in that: In step S6, the improved Shengji Yuhong ointment oil comprises 10 mL of safflower oil, 5 mL of cnidium monnieri oil, 0.5 g of Yuhong ointment, 0.5 g of raw milk, and an appropriate amount of anti-inflammatory and dehumidifying prescription.